Abstract
The present investigation was carried out to formulate and optimize the bioerodable insert of Azithromycin in order to prolong the release time and improve the ocular availability in ophthalmic infections. A modified solvent casting method was used for the preparation of azithromycin insert in which hydroxyl propyl methyl cellulose (HPMC) and Eudragit RL100 were used as drug reservoir and rate controlling membrane respectively. Thereafter the, formulations were evaluated for the uniformity of thickness and weight, surface pH, folding endurance, percentage moisture loss, percentage moisture absorption, drug content, in-vitro release, kinetics studies (zero order, first order, Higuchi and Korsmeyer - Peppas model) and stability studies. The Formulation H8 (amongst the range of H1-H10), comprising of 1.5% HPMC and 3% Eudragit RL100, was found to be optimized formulation on the basis of uniformity of thickness (0.26±0.004 mm) and weight (24.9±0.27 mg), surface pH (7.1±0.063), folding endurance (18.3±0.81), percentage moisture loss (7.49±0.30%), percentage moisture absorption (5.7%), drug content (1.98 mg), in-vitro release (99%), AUC for in vitro and in vivo release is 38828.33 and 39783.33 g min/ml respectively and higher than pure drug (1190 g min/ml), (Shelf life- 622 days) and further better occular tolerablity found. The formulation H8 showed a steady and controlled release of the drug over a 12 hour period with non-Fickian diffusion release mechanism, compared to a normal release period of 2-3 hours. The optimized insert showed promising results and can be used to treat a wide range of ocular infections.
Keywords: Azithromycin, Biodegradable polymers, Flicks law, Ocular test.
Current Drug Delivery
Title:Development and Optimization of Controlled Release Bioerodable Anti Infective Ophthalmic Insert
Volume: 11 Issue: 1
Author(s): Richa Thakur, Gaurav Swami and Mahfoozur Rahman
Affiliation:
Keywords: Azithromycin, Biodegradable polymers, Flicks law, Ocular test.
Abstract: The present investigation was carried out to formulate and optimize the bioerodable insert of Azithromycin in order to prolong the release time and improve the ocular availability in ophthalmic infections. A modified solvent casting method was used for the preparation of azithromycin insert in which hydroxyl propyl methyl cellulose (HPMC) and Eudragit RL100 were used as drug reservoir and rate controlling membrane respectively. Thereafter the, formulations were evaluated for the uniformity of thickness and weight, surface pH, folding endurance, percentage moisture loss, percentage moisture absorption, drug content, in-vitro release, kinetics studies (zero order, first order, Higuchi and Korsmeyer - Peppas model) and stability studies. The Formulation H8 (amongst the range of H1-H10), comprising of 1.5% HPMC and 3% Eudragit RL100, was found to be optimized formulation on the basis of uniformity of thickness (0.26±0.004 mm) and weight (24.9±0.27 mg), surface pH (7.1±0.063), folding endurance (18.3±0.81), percentage moisture loss (7.49±0.30%), percentage moisture absorption (5.7%), drug content (1.98 mg), in-vitro release (99%), AUC for in vitro and in vivo release is 38828.33 and 39783.33 g min/ml respectively and higher than pure drug (1190 g min/ml), (Shelf life- 622 days) and further better occular tolerablity found. The formulation H8 showed a steady and controlled release of the drug over a 12 hour period with non-Fickian diffusion release mechanism, compared to a normal release period of 2-3 hours. The optimized insert showed promising results and can be used to treat a wide range of ocular infections.
Export Options
About this article
Cite this article as:
Thakur Richa, Swami Gaurav and Rahman Mahfoozur, Development and Optimization of Controlled Release Bioerodable Anti Infective Ophthalmic Insert, Current Drug Delivery 2014; 11 (1) . https://dx.doi.org/10.2174/15672018113106660060
DOI https://dx.doi.org/10.2174/15672018113106660060 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acellular Spinal Cord Scaffold Implantation Promotes Vascular Remodeling with Sustained Delivery of VEGF in a Rat Spinal Cord Hemisection Model
Current Neurovascular Research Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Evaluation of Cell Tolerability of a Series of Lipoamino Acids Using Biological Membranes and a Biomembrane Model.
Current Drug Delivery Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in Pathophysiology of Traumatic Brain Injury
Current Neuropharmacology Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Antidiabetic Effect of Spearmint in Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Evaluating the Risk of Covid-19 Transmission from Conjunctival and Lacrimal Discharge: A Review
Current Biotechnology Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Current Drug Delivery Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology